Journal article
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, Hans-Peter Boeck, Roland Repp, Hannes Wandt, Christiane Pott, John F Seymour, Bernd Metzner, Annette Haenel, Tanja Lehmann, Frank Hartmann, Hermann Einsele, Wolfgang Hiddemann
Blood | AMER SOC HEMATOLOGY | Published : 2006